Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 14/20 | 0.44 |
| ▸ | MMP3 | P08254 | 8/20 | 0.44 |
| ▸ | MMP12 | P39900 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7758482 | 0.78 | MMP2 (0.62) | MMP2MMP3 | |
| SCHEMBL7758573 | 0.78 | MMP2 (0.71) | MMP2MMP3 | |
| SCHEMBL7048897 | 0.73 | MMP2 (0.36) | MMP2MMP3MMP12MMP1MMP9 | |
| SCHEMBL7761249 | 0.71 | MMP2 (0.60) | MMP2MMP3 | |
| SCHEMBL9289897 | 0.65 | MMP3 (0.58) | MMP2MMP3MMP1 | |
| SCHEMBL7763695 | 0.64 | MMP2 (0.73) | MMP2MMP3 | |
| SCHEMBL7758741 | 0.64 | MMP2 (0.69) | MMP2MMP3 | |
| SCHEMBL7763165 | 0.63 | MMP3 (0.56) | MMP2MMP3MMP1MMP9 | |
| SCHEMBL5613483 | 0.63 | MMP12 (1.00) | MMP2MMP3MMP12MMP13MMP9 | |
| SCHEMBL3466543 | 0.62 | MMP12 (0.51) | MMP2MMP3MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |